Colorectal Cancer Stem Cell Biomarkers: Biological Traits and Prognostic Insights

IF 2.6 4区医学 Q2 PHARMACOLOGY & PHARMACY

Current pharmaceutical design Pub Date : 2024-04-16 DOI:10.2174/0113816128291321240329050945

Atena Soleimani, Nikoo Saeedi, Abdulridha Mohammed Al-Asady, Elnaz Nazari, Reyhane Hanaie, Majid Khazaei, Elnaz Ghorbani, Hamed Akbarzade, Mikhail Ryzhikov, Amir Avan, Seyed Mahdi Hasanian Mehr

{"title":"Colorectal Cancer Stem Cell Biomarkers: Biological Traits and Prognostic Insights","authors":"Atena Soleimani, Nikoo Saeedi, Abdulridha Mohammed Al-Asady, Elnaz Nazari, Reyhane Hanaie, Majid Khazaei, Elnaz Ghorbani, Hamed Akbarzade, Mikhail Ryzhikov, Amir Avan, Seyed Mahdi Hasanian Mehr","doi":"10.2174/0113816128291321240329050945","DOIUrl":null,"url":null,"abstract":": Due to self-renewal, differentiation, and limitless proliferation properties, Cancer Stem Cells (CSCs) increase the probability of tumor development. These cells are identified by using CSC markers, which are highly expressed proteins on the cell surface of CSCs. Recently, the therapeutic application of CSCs as novel biomarkers improved both the prognosis and diagnosis outcome of colorectal Cancer. In the present review, we focused on a specific panel of colorectal CSC markers, including LGR5, ALDH, CD166, CD133, and CD44, which offers a targeted and comprehensive analysis of their functions. The selection criteria for these markersCancer were based on their established significance in Colorectal Cancer (CRC) pathogenesis and clinical outcomes, providing novel insights into the CSC biology of CRC. Through this approach, we aim to elevate understanding and stimulate further research for developing effective diagnostic and therapeutic strategies in CRC.","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":"123 1","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128291321240329050945","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

: Due to self-renewal, differentiation, and limitless proliferation properties, Cancer Stem Cells (CSCs) increase the probability of tumor development. These cells are identified by using CSC markers, which are highly expressed proteins on the cell surface of CSCs. Recently, the therapeutic application of CSCs as novel biomarkers improved both the prognosis and diagnosis outcome of colorectal Cancer. In the present review, we focused on a specific panel of colorectal CSC markers, including LGR5, ALDH, CD166, CD133, and CD44, which offers a targeted and comprehensive analysis of their functions. The selection criteria for these markersCancer were based on their established significance in Colorectal Cancer (CRC) pathogenesis and clinical outcomes, providing novel insights into the CSC biology of CRC. Through this approach, we aim to elevate understanding and stimulate further research for developing effective diagnostic and therapeutic strategies in CRC.

查看原文本刊更多论文

结直肠癌干细胞生物标志物：生物特征和预后洞察力

:癌症干细胞（CSC）具有自我更新、分化和无限增殖的特性，会增加肿瘤发展的几率。癌干细胞标记物是癌干细胞细胞表面高表达的蛋白质，可通过癌干细胞标记物识别癌干细胞。最近，CSCs 作为新型生物标志物在治疗上的应用改善了结直肠癌的预后和诊断结果。在本综述中，我们重点研究了一组特定的结直肠癌 CSC 标志物，包括 LGR5、ALDH、CD166、CD133 和 CD44，从而对它们的功能进行了有针对性的全面分析。这些标记物的选择标准是基于它们在结直肠癌（CRC）发病机制和临床结果中的既定意义，从而为了解 CRC 的 CSC 生物学提供新的视角。通过这种方法，我们希望加深对 CRC 的了解，并促进进一步的研究，以开发有效的诊断和治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current pharmaceutical design 医学-药学

CiteScore

6.30

自引率

0.00%

发文量

302

审稿时长

2 months

期刊介绍： Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.